MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One donor, two transplants: new hope for patients with blood cancer and kidney failure
Disease control CompletedThis study tested a combined bone marrow and kidney transplant from a partially matched family donor for 10 people with both a serious blood disorder and chronic kidney disease. The goal was to treat both conditions with one donor, potentially reducing the need for lifelong anti-…
Matched conditions: MYELOFIBROSIS
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
Drug dasatinib shows promise for rare blood cancers
Disease control CompletedThis study tested the drug dasatinib in 68 adults with several blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control these diseases and to check its safety. Results focused on how many pa…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:08 UTC
-
New hope for myelofibrosis patients after failed standard therapies?
Disease control CompletedThis study tested a drug called itacitinib in 4 people with a type of bone marrow cancer called myelofibrosis. All participants had already tried other treatments (ruxolitinib or fedratinib) without success. The main goals were to check safety and see if the drug could shrink an …
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo shows promise for rare blood cancers
Disease control CompletedThis study tested a new pill called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. The goal was to see if it could shrink enlarged spleens and reduce the need for blood transfusions. The drug was given alone or with another medicine (ruxoli…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Healthy volunteers help test drug interactions for myelofibrosis treatment
Knowledge-focused CompletedThis study looked at how certain drugs that affect liver enzymes change the way TQ05105 tablets are processed in the body. It involved 40 healthy adults aged 18 to 45. The goal was to understand safety and drug levels, not to treat the disease.
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 05:27 UTC
-
Real-World data reveals treatment patterns for rare blood cancer in turkey
Knowledge-focused CompletedThis study reviewed medical records of 355 people in Turkey with myelofibrosis, a rare bone marrow cancer, who were treated with the drug ruxolitinib for at least 3 months. Researchers looked at patient characteristics, lab results, and how the disease was managed in everyday pra…
Matched conditions: MYELOFIBROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 17, 2026 05:09 UTC
-
Personalized plans may boost transplant survival in seniors
Knowledge-focused CompletedThis study tested a personalized geriatric optimization plan (GO!) in 30 patients aged 60 and older who were getting a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see …
Matched conditions: MYELOFIBROSIS
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 12, 2026 13:42 UTC